Inhibition of G protein-activated inwardly rectifying K+ channels by the antidepressant paroxetine

Journal of Pharmacological Sciences

Volumn 102, Issue 3, 2006, Pages 278-287

  Kobayashi, Toru ^a   Washiyama, Kazuo ^a   Ikeda, Kazutaka ^b  

^a NIIGATA UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Antidepressant; Ethanol; G protein activated inwardly rectifying K + (GIRK) channel; Paroxetine; Xenopus oocyte

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ANTIDEPRESSANT AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; MILNACIPRAN; PAROXETINE; POTASSIUM CHANNEL; TRAZODONE;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART RATE; NERVE CELL EXCITABILITY; NONHUMAN; OOCYTE; PROTEIN EXPRESSION; XENOPUS;

EID: 33751213928     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0060708     Document Type: Article

References (58)

1. Baldessarini RJ. Drugs and the treatment of psychiatric disorders: depression and anxiety disorders. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001. p. 447-483.
2. Bourin M, Chue P, Guillon Y. Paroxetine: A review. CNS Drug Rev. 2001;7:25-47.
3. Stanton T, Bolden-Watson C, Cusack B, Richelson E. Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistamines. Biochem Pharmacol. 1993;45:2352-2354.
4. Fryer JD, Lukas RJ. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. J Neurochem. 1999;72:1117-1124.
5. Maertens C, Droogmans G, Verbesselt R, Nilius B. Block of volume-regulated anion channels by selective serotonin reuptake inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2002;366:158-165.
6. Pariante CM, Makoff A, Lovestone S, Feroli S, Heyden A, Miller AH, et al. Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. Br J Pharmacol. 2001;134:1335-1343.
7. Finkel MS, Laghriss-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull. 1996;32:653-658.
8. + channels by fluoxetine (Prozac). Br J Pharmacol. 2003;138:1119-1128.
9. + channels by various antidepressant drugs. Neuropsychopharmacology. 2004;29:1841-1851.
10. + channel: Expression cloning and molecular properties. Proc Natl Acad Sci U S A. 1993;90:10235-10239.
11. Kubo Y, Reuveny E, Slesinger PA, Jan YN, Jan LY. Primary structure and functional expression of a rat G-protein-coupled muscarinic potassium channel. Nature. 1993;364:802-806.
12. + channels. J Biol Chem.1995;270:28660-28667.
13. Wickman K, Seldin MF, Gendler SJ, Clapham DE. Partial structure, chromosome localization, and expression of the mouse Girk4 gene. Genomics. 1997;40:395-401.
14. Reimann F, Ashcroft FM. Inwardly rectifying potassium channels. Curr Opin Cell Biol. 1999;11:503-508.
15. + channel (mGIRK1) and distinct distributions of three GIRK (GIRK1, 2 and 3) mRNAs in mouse brain. Biochem Biophys Res Commun. 1995;208:1166-1173.
16. + channel mRNAs are differentially expressed in the adult rat brain. J Neurosci. 1996;16:3559-3570.
17. + channel proteins GIRK1 and GIRK2 and their altered expression in weaver brain. J Neurosci. 1996;16:7137-7150.
18. + channels composed of Kir3.2 subunits in dopaminergic neurons of the substantia nigra. J Neurosci. 1999;19:1006-1017.
19. +-channel proteins. Nature. 1995;374:135-141.
20. North RA. Drug receptors and the inhibition of nerve cells. Br J Pharmacol. 1989;98:13-28.
21. + (GIRK) channel. Mol Brain Res. 1997;45:117-126.
22. + (GIRK) channels and functional couplings of the opioid receptors with the GIRK1 channel. Ann N Y Acad Sci. 1996;801:95-109.
23. + channel. Biochem Biophys Res Commun. 1995;208:302-308.
24. Reuveny E, Slesinger PA, Inglese J, Morales JM, Iniguez-Lluhi JA, Lefkowitz RJ, et al. Activation of the cloned muscarinic potassium channel by G protein βγ subunits. Nature. 1994;370:143-146.
25. + channels. Nat Neurosci. 1999;2:1091-1097.
26. Lewohl JM, Wilson WR, Mayfield RD, Brozowski SJ, Morrisett RA, Harris RA. G-protein-coupled inwardly rectifying potassium channels are targets of alcohol action. Nat Neurosci. 1999;2:1084-1090.
27. + channel GIRK2. Proc Natl Acad Sci U S A. 1997;94:923-927.
28. Wickman K, Nemec J, Gendler SJ, Clapham DE. Abnormal heart rate regulation in GIRK4 knockout mice. Neuron. 1998;20:103-114.
29. KACh. J Biol Chem. 2002;277:48282-48288.
30. + channels: potentially therapeutic agents for addictive drug users. Ann N Y Acad Sci. 2004;1025:590-594.
31. + (GIRK) channels expressed in Xenopus oocytes. Br J Pharmacol. 2000;129:1716-1722.
32. Kobayashi T, Ikeda K, Kumanishi T. Functional characterization of an endogenous Xenopus oocyte adenosine receptor. Br J Pharmacol. 2002;135:313-322.
33. Ho K, Nichols CG, Lederer WJ, Lytton J, Vassilev PM, Kanazirska MV, et al. Cloning and expression of an inwardly rectifying ATP-regulated potassium channel. Nature. 1993;362:31-38.
34. Kubo Y, Baldwin TJ, Jan YN, Jan LY. Primary structure and functional expression of a mouse inward rectifier potassium channel. Nature. 1993;362:127-133.
35. Ikeda K, Yoshii M, Sora I, Kobayashi T. Opioid receptor coupling to GIRK channels. In vitro studies using a Xenopus oocyte expression system and in vivo studies on weaver mutant mice. Methods Mol Med. 2003;84:53-64.
36. + channels by ifenprodil. Neuropsychopharmacology. 2006;31:516-524.
37. + channels. Cell Signal. 1997;9:551-573.
38. + channels. Proc Natl Acad Sci U S A. 2001;98:6482-6487.
39. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TCG, Zussman BD, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand. 1989;89 Suppl 350:60-75.
40. Henry ME, Moore CM, Kaufman MJ, Michelson D, Schmidt ME, Stoddard E, et al. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. Am J Psychiatry. 2000;157:1506-1508.
41. Kuzhikandathil EV, Oxford GS. Classic D1 dopamine receptor antagonist R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH23390) directly inhibits G protein-coupled inwardly rectifying potassium channels. Mol Pharmacol. 2002;62:119-126.
42. Blednov YA, Stoffel M, Chang SR, Harris RA. Potassium channels as targets for ethanol: studies of G-protein-coupled inwardly rectifying potassium channel 2 (GIRK2) null mutant mice. J Pharmacol Exp Ther. 2001;298:521-530.
43. Lightowler S, Kennett GA, Willamson IJR, Blackburn TP, Tulloch IF. Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav. 1994;49:281-285.
44. Hascoët M, Bourin M, Colombel MC, Fiocco AJ, Baker GB. Anxiolytic-like effects of antidepressants after administration in a four-plate test in mice. Pharmacol Biochem Behav. 2000;65:339-344.
45. Brocco M, Dekeyne A, Veiga S, Girardon S, Millan MJ. Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents. Pharmacol Biochem Behav. 2002;71:667-680.
46. Joffe RT, Levitt AJ, Sokolov ST, Young LT. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry. 1996;57:114-115.
47. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58 Suppl 13:23-29.
48. + channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron. 1997;19:687-695.
49. Torrecilla M, Marker CL, Cintora SC, Stoffel M, Williams JT, Wickman K. G-protein-gated inwardly rectifying potassium channels containing Kir3.2 and Kir3.3 subunits mediate the acute inhibitory effects of opioids on locus ceruleus neurons. J Neurosci. 2002;22:4328-4334.
50. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42:277-285.
51. Hamilton TC, Norton J, Poyser RH, Thormählen D. Comparison of some effects of paroxetine with amitriptyline on the cardiovascular system in animals. Arzneim Forsch. 1986;36:460-463.
52. Vermeulen T. Distribution of paroxetine in three postmortem cases. J Anal Toxicol. 1998;22:541-544.
53. Goeringer KE, Raymon L, Christian GD, Logan BK. Postmortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases. J Forensic Sci. 2000;45:633-648.
54. Brown AM, Birnbaumer L. Ionic channels and their regulation by G protein subunits. Annu Rev Physiol. 1990;52:197-213.
55. Gulley JM, McNamara C, Barbera TJ, Ritz MC, Beorge FR. Selective serotonin reuptake inhibitors: effects of chronic treatment on ethanol-reinforced behavior in mice. Alcohol. 1995;12:177-181.
56. Maurel S, Devry J, Schreiber R. Comparison of the effects of the selective serotonin-reuptake inhibitors fluoxetine, paroxetine, citalopram and fluvoxamine in alcohol-preferring cAA rats. Alcohol. 1999;17:195-201.
57. Randall CL, Johnson MR, Thevos AK, Sonne SC, Thomas SE, Willard SL, et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depression Anxiety. 2001;14:255-262.
58. Hill KG, Alva H, Blednov YA, Cunningham CL. Reduced ethanol-induced conditioned taste aversion and conditioned place preference in GIRK2 null mutant mice. Psychopharmacology. 2003;169:108-114.